drugset / Trial / NCT06474377
Clinical Trial of PCV24 in Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in adults aged 18 years and older. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled Phase I clinical trial.
Timeline
- Start
- 2024-06-21
- Primary completion
- 2024-08-26
- Completion
- 2025-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV24 formulation 1 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV24 formulation 2 | Vaccine | 0.5 ml | Intramuscular |